Efficacy of Topical Liposomal Amphotericin B versus Intralesional Meglumine Antimoniate (Glucantime) in the Treatment of Cutaneous Leishmaniasis

Table 1

Demographic and cutaneous leishmaniasis characteristics of the studied population.

	Intralesional glucantime	Liposomal amphotericin B	P value
No. of patients	60	50
Sex
Male	21	23	0.241
Female	39	27
Age
(mean ± SD)	25.30 ± 15.70	20.54 ± 18.72	0.150
No. of lesions	1.4 ± 0.76	1.91 ± 1.02	<0.05
(mean ± SD)
Duration of lesions (week)	3.84 ± 1.75	4.24 ± 1.24	0.166
Type of lesions
Papuloplaque	53	33	0.011
Nodule	5	8
Ulcer	2	9
Location of lesions
Head and neck	22	26	0.185
Hand	32	18
Leg and trunk	6	6